Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Immunoglobulin Light-chain Amyloidosis 3Pleural Effusion, Malignant 2Amyloidosis 2Tuberous Sclerosis 1Skin Toxicity 1Ras-wildtype Colorectal Cancer 1Polycystic Ovary Syndrome 1Pancreatic Neoplasms 1Pain 1Neoplasm Metastasis 1Menstruation Disturbances 1Lymphoma, Non-Hodgkin 1Lymphangioleiomyomatosis 1Intracranial Aneurysm 1Hyperandrogenism 1Hemangioma, Cavernous 1Head and Neck Neoplasms 1Exanthema 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Arteriovenous Malformations 1Amyloidosis, Familial 1Advanced Malignant Neoplasm 1AA amyloidosis 1

Interventions

Carboplatin 7Paclitaxel 6Talc 5Docetaxel 5Bevacizumab 4Taxes 3Gemcitabine 3Cisplatin 3Trastuzumab 2High-Energy Shock Waves 2Erlotinib Hydrochloride 2Doxycycline 2Cetuximab 2Bortezomib 2viscum album peptide 1tipifarnib 1saracatinib 1romidepsin 1endostar protein 1Zoledronic Acid 1Vinorelbine 1Valacyclovir 1Tyrosine Kinase Inhibitors 1Thoracoscopy 1Thoracoscopes 1Thoracic Surgery, Video-Assisted 1Thoracentesis 1Surveys and Questionnaires 1Sorafenib 1Povidone-Iodine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Pleural Effusion, Malignant × Doxycycline × Clear all
NCT00002872 2023-06-22

Bleomycin, Doxycycline, or Talc in Treating Patients With Malignant Pleural Effusions

Eastern Cooperative Oncology Group

Phase 3 Completed
480 enrolled
Thoracic

Neoplasm Metastasis, Pleural Effusion, Malignant

NCT02583282 2022-10-06

A Study to Compare the Efficacy and Safety of Intrapleural Doxycycline Versus Iodopovidone for Performing Pleurodesis in Malignant Pleural Effusion

Post Graduate Institute of Medical Education and Research, Chandigarh

Phase NA Completed
100 enrolled
Thoracic

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡